Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children
Background. Modern therapy programs allow achieving high survival rates in children with acute lymphoblastic leukemia (ALL). However, there is a group of patients in whom a relapse occurs, which makes it necessary to search for optimal tools for monitoring remission and the earliest detection of ALL...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Habib O.N.
2020-05-01
|
Series: | Современная онкология |
Subjects: | |
Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/34006/21716 |
_version_ | 1818287733622177792 |
---|---|
author | Meri A. Shervashidze Timur T. Valiev Natalia A. Batmanova Nikolai N. Tupitsyn Irina N. Serebryakova |
author_facet | Meri A. Shervashidze Timur T. Valiev Natalia A. Batmanova Nikolai N. Tupitsyn Irina N. Serebryakova |
author_sort | Meri A. Shervashidze |
collection | DOAJ |
description | Background. Modern therapy programs allow achieving high survival rates in children with acute lymphoblastic leukemia (ALL). However, there is a group of patients in whom a relapse occurs, which makes it necessary to search for optimal tools for monitoring remission and the earliest detection of ALL relapse. According to clinical and immunological studies, assessment of minimal residual disease (MRD) levels is one of the leading criteria for response to treatment and can be the basis for risk-stratified therapy.
Aim. Assessment of MRD levels on the 15th day of induction as the main parameter for stratification of patients into prognostic risk groups and the impact of MOB levels on patient survival.
Materials and methods. The study included 117 children with a newly diagnosed precursor B-cell ALL. All patients were given an induction course according to the BFM ALL IC 2009 protocol.
MRD levels were determined by flow cytometry.
Results. Given the MRD based stratification, a truly standard risk group was identified, the survival rate of which reached 100%.
Conclusions. The use of MRD as the main tool for the risk of adapted therapy made it possible to improve survival in patients of the standard risk group, as well as to optimize therapy for high and medium risk groups in the future. |
first_indexed | 2024-12-13T01:45:11Z |
format | Article |
id | doaj.art-79e213ecc00840e39b10e161994306f2 |
institution | Directory Open Access Journal |
issn | 1815-1434 1815-1442 |
language | Russian |
last_indexed | 2024-12-13T01:45:11Z |
publishDate | 2020-05-01 |
publisher | IP Habib O.N. |
record_format | Article |
series | Современная онкология |
spelling | doaj.art-79e213ecc00840e39b10e161994306f22022-12-22T00:03:39ZrusIP Habib O.N.Современная онкология1815-14341815-14422020-05-01214222610.26442/18151434.2019.4.19074530677Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in childrenMeri A. Shervashidze0Timur T. Valiev1Natalia A. Batmanova2Nikolai N. Tupitsyn3Irina N. Serebryakova4Blokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyBackground. Modern therapy programs allow achieving high survival rates in children with acute lymphoblastic leukemia (ALL). However, there is a group of patients in whom a relapse occurs, which makes it necessary to search for optimal tools for monitoring remission and the earliest detection of ALL relapse. According to clinical and immunological studies, assessment of minimal residual disease (MRD) levels is one of the leading criteria for response to treatment and can be the basis for risk-stratified therapy. Aim. Assessment of MRD levels on the 15th day of induction as the main parameter for stratification of patients into prognostic risk groups and the impact of MOB levels on patient survival. Materials and methods. The study included 117 children with a newly diagnosed precursor B-cell ALL. All patients were given an induction course according to the BFM ALL IC 2009 protocol. MRD levels were determined by flow cytometry. Results. Given the MRD based stratification, a truly standard risk group was identified, the survival rate of which reached 100%. Conclusions. The use of MRD as the main tool for the risk of adapted therapy made it possible to improve survival in patients of the standard risk group, as well as to optimize therapy for high and medium risk groups in the future.https://modernonco.orscience.ru/1815-1434/article/viewFile/34006/21716acute lymphoblastic leukemiaminimal residual diseasechildrenrisk-adopted therapychildren |
spellingShingle | Meri A. Shervashidze Timur T. Valiev Natalia A. Batmanova Nikolai N. Tupitsyn Irina N. Serebryakova Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children Современная онкология acute lymphoblastic leukemia minimal residual disease children risk-adopted therapy children |
title | Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children |
title_full | Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children |
title_fullStr | Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children |
title_full_unstemmed | Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children |
title_short | Modern immunological criteria for a stratification of risk groups for precursor B cell acute lymphoblastic leukemia in children |
title_sort | modern immunological criteria for a stratification of risk groups for precursor b cell acute lymphoblastic leukemia in children |
topic | acute lymphoblastic leukemia minimal residual disease children risk-adopted therapy children |
url | https://modernonco.orscience.ru/1815-1434/article/viewFile/34006/21716 |
work_keys_str_mv | AT meriashervashidze modernimmunologicalcriteriaforastratificationofriskgroupsforprecursorbcellacutelymphoblasticleukemiainchildren AT timurtvaliev modernimmunologicalcriteriaforastratificationofriskgroupsforprecursorbcellacutelymphoblasticleukemiainchildren AT nataliaabatmanova modernimmunologicalcriteriaforastratificationofriskgroupsforprecursorbcellacutelymphoblasticleukemiainchildren AT nikolaintupitsyn modernimmunologicalcriteriaforastratificationofriskgroupsforprecursorbcellacutelymphoblasticleukemiainchildren AT irinanserebryakova modernimmunologicalcriteriaforastratificationofriskgroupsforprecursorbcellacutelymphoblasticleukemiainchildren |